Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DB818 is a synthetic Homeobox A9 (HOXA9) inhibitor and can be used for research on the treatment of acute myeloid leukaemia associated with HOXA9 overexpression.
Description | DB818 is a synthetic Homeobox A9 (HOXA9) inhibitor and can be used for research on the treatment of acute myeloid leukaemia associated with HOXA9 overexpression. |
In vitro | In the three AML cell lines, DB818 suppressed growth, induced apoptosis, and down-regulated the expression of HOXA9 transcriptional target genes: MYB proto-oncogene, transcription factor (MYB), MYC proto-oncogene, bHLH transcription factor (MYC), and BCL2 apoptosis regulator (BCL2), while up-regulating that of Fos proto-oncogene, AP-1 transcription factor subunit (FOS). HOXA9 knockdown showed similar effects, except for MYC expression, which differed between DB818-treated and HOXA9-deficient OCI/AML3 cells, suggesting an off-target effect of DB818[1]. |
Molecular Weight | 360.44 |
Formula | C19H16N6S |
CAS No. | 790241-43-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 35.71 mg/mL (99.09 mM), Sonication is recommended.
DMSO: <3.6 mg/mL (10 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
DB818 790241-43-9 Others DB-818 DB 818 inhibitor inhibit